How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/persistent-pulmonary-hypertension-of-the-newborn.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Persistent pulmonary hypertension of the newborn — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Persistent pulmonary hypertension of the newborn (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Persistent pulmonary hypertension of the newborn, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Inomax	NITRIC OXIDE	Vero Biotech Inc	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Vasodil	TOLAZOLINE	Novartis	tolazoline	Alpha-2A adrenergic receptor	1948-01-01
NITROGEN, NF	NITROGEN, NF	UNIVERSAL INDUSTRIAL GASES, INC

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis · 1 drug in Persistent pulmonary hypertension of the newborn
UNIVERSAL INDUSTRIAL GASES, INC · 1 drug in Persistent pulmonary hypertension of the newborn
Vero Biotech Inc · 1 drug in Persistent pulmonary hypertension of the newborn

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Persistent pulmonary hypertension of the newborn:

Cite this brief

Drug Landscape (2026). Persistent pulmonary hypertension of the newborn — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/persistent-pulmonary-hypertension-of-the-newborn. Accessed 2026-06-10.

Persistent pulmonary hypertension of the newborn full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing